This study analyses health‐related quality of life data from 8 randomized clinical trials using ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin to investigate: (i) the impact of the treatment vs placebo during… Click to show full abstract
This study analyses health‐related quality of life data from 8 randomized clinical trials using ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin to investigate: (i) the impact of the treatment vs placebo during treatment on health‐related quality of life; (ii) the sustainability of such treatment effect after 12‐week treatment period; and (iii) if results from (i) and (ii) differ in subgenotypes 1a vs 1b.
               
Click one of the above tabs to view related content.